MAIA Biotechnology(MAIA)

CHICAGO, ILBiotechnology1 H-1B visas (FY2023)

Focus: MAIA Biotechnology is a public biotech company focused on peptide-based cancer therapies with a pipeline spanning Phase 1–3 oncology programs. The company operates at a modest scale with minimal current revenue generation and a focused R&D agenda.

Oncology

Profile data last refreshed 5h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About MAIA Biotechnology

AI assessmentNot Hiring

No open roles listed right now. Follow MAIA Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

6/9 — Partial

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

Key Products

BACLOFEN

Multiple sclerosis, skeletal muscle spasm, Parkinson's disease

Post-LOE

Off-patent GABA agonist; generates legacy revenue but faces generic competition and declining therapeutic relevance.

Help build intelligence for MAIA Biotechnology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused oncology mission with three active pipeline programs in Phase 1–3, offering clinical development exposure in a high-impact therapeutic area.
Public company status provides equity upside potential and access to public capital markets for funding R&D expansion.
Proprietary peptide therapeutic platform represents differentiated science in a competitive oncology landscape.

Watch Out For

Severe cash burn with $23.3M net loss in FY 2025 and only $454K R&D spend (down from $11M in FY 2024), signaling financial stress and potential runway constraints.
Zero active job openings and minimal hiring activity despite public status suggest limited headcount growth or restructuring risk ahead.
Early-stage pipeline (only 3 programs total, with only 1 in Phase 3) offers limited near-term catalysts and revenue visibility to support long-term employment stability.

Generated by Claude from MAIA Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

SODIUM PHENYLACETATE AND SODIUM BENZOATE

Urea cycle disorder support

Peak

Peak-lifecycle NDA product addressing rare metabolic disorders; core revenue driver with durable market position.

DAPTOMYCIN

Infectious disease

Growth

Growth-phase NDA antibacterial with expanding clinical utility in serious infections.

BORTEZOMIB

Multiple myeloma, lymphoma

Peak16.1yr

Blockbuster proteasome inhibitor with patent protection extending to 2042; long-term revenue contributor.